AI Produces History of Present Illness Summaries Comparable With Residents
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, July 20, 2023 -- History of present illness (HPI) writeups are of similar quality whether written by a chatbot or senior internal medicine residents, according to a study published online July 17 in JAMA Internal Medicine.
Ashwin Nayak, M.D., from Stanford University in California, and colleagues evaluated the ability of a chatbot to generate an HPI compared with senior internal medicine residents. The analysis included HPIs generated by ChatGPT and those written by four residents based on three patient interview scripts portraying different types of chest pain.
The researchers found that the acceptance rate for chatbot-generated HPIs improved from 10.0 to 43.3 percent by the final round of prompt engineering. Based on the 15-point composite scale, grades of resident and chatbot-generated HPIs differed by less than 1 point (resident mean, 12.18, versus chatbot mean, 11.23). Resident HPIs scored higher on level of detail scale (resident mean, 4.13, versus chatbot mean, 3.57). HPIs were correctly characterized as written by residents or the chatbot by attending physicians 61 percent of the time.
"These findings underscore the potential of chatbots to aid clinicians with medical documentation," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.